|Dr. Kevin C. Gorman||CEO & Director||1.15M||22.04M||1958|
|Mr. Matthew C. Abernethy||Chief Financial Officer||689.24k||N/A||1981|
|Mr. Kyle W. Gano||Chief Bus. Devel. and Strategy Officer||602.64k||4.93M||1973|
|Mr. Eric S. Benevich||Chief Commercial Officer||676.85k||N/A||1965|
|Ms. Eiry Wyn Roberts||Chief Medical Officer||1.39M||N/A||1964|
Neurocrine Biosciences, Inc. discovers and develops treatments for patients with neurological, endocrine, and psychiatric disorders. The company offers INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of adults with tardive dyskinesia; and ORILISSA (elagolix) for the management of moderate to severe endometriosis pain in women in the United States. It also develops opicapone, a catechol-o-methyltransferase inhibitor, for the treatment of Parkinson's disease patients; crinecerfont for the treatment of congenital adrenal hyperplasia; and NBIb-1817, an investigational gene therapy for the treatment of Parkinson's disease. In addition, the company is developing NBI-921352, an inhibitor being developed to treat pediatric patients with SCN8A-DEE and other potential indications, including adult focal epilepsy; and ACT-709478, an orally active and brain penetrating T-type calcium channel blocker for potential use in certain forms of generalized epilepsy. Neurocrine Biosciences, Inc. has collaboration agreements with AbbVie Inc.; Mitsubishi Tanabe Pharma Corporation; BIAL Portela & Ca, S.A.; Jnana Therapeutics Inc.; Voyager Therapeutics, Inc.; and Xenon Pharmaceuticals Inc. Neurocrine Biosciences, Inc. was incorporated in 1992 and is headquartered in San Diego, California.
Neurocrine Biosciences, Inc.’s ISS Governance QualityScore as of December 4, 2019 is 5. The pillar scores are Audit: 1; Board: 8; Shareholder Rights: 5; Compensation: 4.